Telomeres do not always shorten over time in individuals with type 1 diabetes

Behalf FinnDiane Study Grp; Anna Syreeni; Luke M. Carroll; Stefan Mutter; Andrzej S. Januszewski; Carol Forsblom; Markku Lehto; Per-Henrik Groop; Alicia J. Jenkins

doi:10.1016/j.diabres.2022.109926

Telomeres do not always shorten over time in individuals with type 1 diabetes

Behalf FinnDiane Study Grp, Anna Syreeni, Luke M. Carroll, Stefan Mutter, Andrzej S. Januszewski, Carol Forsblom, Markku Lehto, Per-Henrik Groop, Alicia J. Jenkins

Research output: Contribution to journal › Article › Scientific › peer-review

Abstract

Aims
We aimed to determine how white blood cell (WBC) telomeres and telomere length change over time are associated with health status in type 1 diabetes.

Methods
Relative telomere length (rTL) was measured in WBC DNA from two time-points (median 6.8 years apart) in 618 individuals from the Finnish Diabetic Nephropathy Study by quantitative PCR, with interassay CV ≤ 4%.

Results
Baseline rTL correlated inversely with age and was shorter in men. Individuals in the shortest vs. longest rTL tertile had adverse cardiometabolic profiles, worse renal function, and were prescribed more antihypertensive and lipid-lowering drugs. While overall rTL tended to decrease during the median 6.8-years of follow-up, telomeres shortened in 55.3% of subjects, lengthened in 40.0%, and did not change in 4.7%. Baseline rTL correlated inversely with rTL change. Telomere lengthening was associated with higher HDL-Cholesterol (HDL-C), HDL-C/ApoA1, and with antihypertensive drug and (inversely) with lipid-lowering drug commencement during follow-up. Correlates of rTL percentage change per-annum (adjusted model) were baseline BMI, eGFR, previous retinal laser treatment, HDL-C, and HDL-C/ApoA1.

Conclusions
Telomere length measurements may facilitate the treatment and monitoring of the health status of individuals with type 1 diabetes.

Original language	English
Article number	109926
Journal	Diabetes Research and Clinical Practice
Volume	188
Number of pages	7
ISSN	0168-8227
DOIs	https://doi.org/10.1016/j.diabres.2022.109926
Publication status	Published - Jun 2022
MoE publication type	A1 Journal article-refereed

Fields of Science

Type 1 diabetes
Telomere
Telomere length change
Kidney function
Obesity
LENGTH
ASSOCIATION
RISK
HEART
DISEASE
NEPHROPATHY
ATTRITION
STATINS
CELLS
3121 General medicine, internal medicine and other clinical medicine

Access to Document

10.1016/j.diabres.2022.109926

Syreeni_Carroll_Mutter_telomeres_Manuscript_2022Accepted author manuscript, 142 KBLicence: CC BY-NC-ND

Cite this

@article{2efbc143f7ed41ecad22ae2c0301c1d1,

title = "Telomeres do not always shorten over time in individuals with type 1 diabetes",

abstract = "AimsWe aimed to determine how white blood cell (WBC) telomeres and telomere length change over time are associated with health status in type 1 diabetes.MethodsRelative telomere length (rTL) was measured in WBC DNA from two time-points (median 6.8 years apart) in 618 individuals from the Finnish Diabetic Nephropathy Study by quantitative PCR, with interassay CV ≤ 4%.ResultsBaseline rTL correlated inversely with age and was shorter in men. Individuals in the shortest vs. longest rTL tertile had adverse cardiometabolic profiles, worse renal function, and were prescribed more antihypertensive and lipid-lowering drugs. While overall rTL tended to decrease during the median 6.8-years of follow-up, telomeres shortened in 55.3% of subjects, lengthened in 40.0%, and did not change in 4.7%. Baseline rTL correlated inversely with rTL change. Telomere lengthening was associated with higher HDL-Cholesterol (HDL-C), HDL-C/ApoA1, and with antihypertensive drug and (inversely) with lipid-lowering drug commencement during follow-up. Correlates of rTL percentage change per-annum (adjusted model) were baseline BMI, eGFR, previous retinal laser treatment, HDL-C, and HDL-C/ApoA1.ConclusionsTelomere length measurements may facilitate the treatment and monitoring of the health status of individuals with type 1 diabetes.",

keywords = "Type 1 diabetes, Telomere, Telomere length change, Kidney function, Obesity, LENGTH, ASSOCIATION, RISK, HEART, DISEASE, NEPHROPATHY, ATTRITION, STATINS, CELLS, 3121 General medicine, internal medicine and other clinical medicine",

author = "{Behalf FinnDiane Study Grp} and Anna Syreeni and Carroll, {Luke M.} and Stefan Mutter and Januszewski, {Andrzej S.} and Carol Forsblom and Markku Lehto and Per-Henrik Groop and Jenkins, {Alicia J.}",

year = "2022",

month = jun,

doi = "10.1016/j.diabres.2022.109926",

language = "English",

volume = "188",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "ELSEVIER IRELAND LTD",

}

TY - JOUR

T1 - Telomeres do not always shorten over time in individuals with type 1 diabetes

AU - Behalf FinnDiane Study Grp

AU - Syreeni, Anna

AU - Carroll, Luke M.

AU - Mutter, Stefan

AU - Januszewski, Andrzej S.

AU - Forsblom, Carol

AU - Lehto, Markku

AU - Groop, Per-Henrik

AU - Jenkins, Alicia J.

PY - 2022/6

Y1 - 2022/6

N2 - AimsWe aimed to determine how white blood cell (WBC) telomeres and telomere length change over time are associated with health status in type 1 diabetes.MethodsRelative telomere length (rTL) was measured in WBC DNA from two time-points (median 6.8 years apart) in 618 individuals from the Finnish Diabetic Nephropathy Study by quantitative PCR, with interassay CV ≤ 4%.ResultsBaseline rTL correlated inversely with age and was shorter in men. Individuals in the shortest vs. longest rTL tertile had adverse cardiometabolic profiles, worse renal function, and were prescribed more antihypertensive and lipid-lowering drugs. While overall rTL tended to decrease during the median 6.8-years of follow-up, telomeres shortened in 55.3% of subjects, lengthened in 40.0%, and did not change in 4.7%. Baseline rTL correlated inversely with rTL change. Telomere lengthening was associated with higher HDL-Cholesterol (HDL-C), HDL-C/ApoA1, and with antihypertensive drug and (inversely) with lipid-lowering drug commencement during follow-up. Correlates of rTL percentage change per-annum (adjusted model) were baseline BMI, eGFR, previous retinal laser treatment, HDL-C, and HDL-C/ApoA1.ConclusionsTelomere length measurements may facilitate the treatment and monitoring of the health status of individuals with type 1 diabetes.

AB - AimsWe aimed to determine how white blood cell (WBC) telomeres and telomere length change over time are associated with health status in type 1 diabetes.MethodsRelative telomere length (rTL) was measured in WBC DNA from two time-points (median 6.8 years apart) in 618 individuals from the Finnish Diabetic Nephropathy Study by quantitative PCR, with interassay CV ≤ 4%.ResultsBaseline rTL correlated inversely with age and was shorter in men. Individuals in the shortest vs. longest rTL tertile had adverse cardiometabolic profiles, worse renal function, and were prescribed more antihypertensive and lipid-lowering drugs. While overall rTL tended to decrease during the median 6.8-years of follow-up, telomeres shortened in 55.3% of subjects, lengthened in 40.0%, and did not change in 4.7%. Baseline rTL correlated inversely with rTL change. Telomere lengthening was associated with higher HDL-Cholesterol (HDL-C), HDL-C/ApoA1, and with antihypertensive drug and (inversely) with lipid-lowering drug commencement during follow-up. Correlates of rTL percentage change per-annum (adjusted model) were baseline BMI, eGFR, previous retinal laser treatment, HDL-C, and HDL-C/ApoA1.ConclusionsTelomere length measurements may facilitate the treatment and monitoring of the health status of individuals with type 1 diabetes.

KW - Type 1 diabetes

KW - Telomere

KW - Telomere length change

KW - Kidney function

KW - Obesity

KW - LENGTH

KW - ASSOCIATION

KW - RISK

KW - HEART

KW - DISEASE

KW - NEPHROPATHY

KW - ATTRITION

KW - STATINS

KW - CELLS

KW - 3121 General medicine, internal medicine and other clinical medicine

U2 - 10.1016/j.diabres.2022.109926

DO - 10.1016/j.diabres.2022.109926

M3 - Article

SN - 0168-8227

VL - 188

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

M1 - 109926

ER -